Denali Therapeutics Inc. (DNLI) fundamentals score
Historically, the blood-brain barrier has been a major challenge to the development of medicines for diseases of the central nervous system. While the blood-brain barrier protects the brain and is essential for its survival, it also prevents the delivery of medicines to the brain in sufficient quantities to have therapeutic effect.
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NASDAQ
Overall: 3.3 out of 10, Unhealthy fundamentals
- Growth: 1.3/10
- Profitability: 1.0/10
- Financial health: 7.5/10
- Earnings quality: 6.7/10
- Valuation: 1.5/10
Scores are calculated from Denali Therapeutics Inc.’s SEC filings, using the 12 months through 2024-12. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10